Inspired by the advantageous effects of A20 depletion on anti-tumor immune activity and being aware of the risk of autoimmunity, we aimed at the development of an A20-inhibition strategy that would limit the side effects as well as the need of any ex vivo DC manipulation. Here, TNFAIP3 is linked to Autoimmunity.